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Abstract
Our study aimed at investigating the distribution, persistence and interchange of viral strains
among peripheral blood mononuclear cells (PBMC), plasma and saliva of primary Epstein-
Barr virus (EBV) infection subjects. Twelve infectious mononucleosis (IM) patients and
eight asymptomatic individuals (AS) with primary EBV infection were followed longitudinally
at several time points for one year from the time of diagnosis, when blood and saliva sam-
ples were collected and separated into PBMC, plasma and saliva, representing circulating
B cell, plasma and epithelial cell compartments, respectively. To survey the viral strains,
genotyping assays for the natural polymorphisms in two latent EBV genes, EBNA2 and
LMP1, were performed and consisted of real-time PCR on EBNA2 to distinguish type 1 and
2 viruses, fluorescent-based 30-bp typing assay on LMP1 to distinguish deletion and wild
type LMP1, and fluorescent-based heteroduplex tracking assays on both EBNA2 and
LMP1 to distinguish defined polymorphic variants. No discernible differences were ob-
served between IM patients and AS. Multiple viral strains were acquired early at the start of
infection. Stable persistence of dominant EBV strains in the same tissue compartment was
observed throughout the longitudinal samples. LMP1-defined strains, China 1, China 2 and
Mediterranean+, were the most common strains observed. EBNA2-defined groups 1 and
3e predominated the PBMC and saliva compartments. Concordance of EBNA2 and LMP1
strains between PBMC and saliva suggested ready interchange of viruses between circulat-
ing B cell and epithelial cell pools, whilst discordance of viral strains observed between plas-
ma and PBMC/saliva indicated presence of viral pools in other undetermined tissue
compartments. Taken together, the results indicated that the distribution, persistence and
interchange of viral strains among the tissue compartments are more complex than those
proposed by the current model of EBV life cycle.
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Introduction
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus infecting more than 90% of the
adult human populations. Most populations in the world are infected by EBV within the first
few years of life. The majority of childhood infections are asymptomatic. Only a minority of
the infected individuals will develop a clinical syndrome known as infectious mononucleosis
(IM), which is characterized by fever, enlarged neck lymph nodes, tonsillopharyngitis
and fatigue.
Two major types of EBV, namely type 1 and type 2 (also known as types A and B), are dis-
tinguished by sequence polymorphisms in Epstein-Barr nuclear antigen (EBNA)-2, -3A, -3B
and -3C genes [1,2]. They occur worldwide but with different geographical distribution. EBV
type 1 (EBV1) predominates in European, American, Chinese and South-east Asian popula-
tions whilst EBV type 2 (EBV2) can only be detected in a minority of healthy carriers in these
populations [3]. On the other hand, a more even distribution of EBV1 and -2 was observed in
African and Papua New Guinean populations [4,5]. Classification by the two EBV types, how-
ever, is not sufficient in revealing the extensive strain diversity of EBV in clinical samples, and
thus, only allows limited understanding of EBV epidemiology. Sequence of EBNA2 gene in
EBV1 was found to harbor stable and constant nucleotide changes [4]. Further analysis of
EBNA2 and Epstein-Barr encoded RNA (EBER) gene sequences of EBV genomes contained in
clinical samples of different malignant and benign EBV-associated diseases identified common
variant strains of EBV1, namely, groups 1, 2, 3a, 3b and 3e [6]. Another highly polymorphic
EBV gene, namely LMP1, is frequently used in molecular epidemiological studies of EBV infec-
tion. The loss of the XhoI restriction site from exon 1 of LMP1 gene was first reported in the
CAO cell line derived from a case of Chinese nasopharyngeal carcinoma (NPC) [7]. A 30-bp
deletion, at the 3’ terminal region of LMP1, which causes the loss of 10 amino acids, was de-
tected in EBV genomes contained in NPC specimens from Taiwan and South China [7,8]. Dif-
ferent patterns of LMP1 sequence variations were later recognized in NPC samples and EBV-
infected lymphoid cell lines and were designated China 1, China 2, and Alaskan strains [9,10].
Two more strains, Mediterranean and North Carolina, were also found when a larger panel of
cell lines and clinical samples of EBV-associated malignancies and non-malignant conditions
such as IM were analyzed [11]. Mediterranean strain is further classified into M+ and M-, indi-
cating the presence (+) or absence (-) of the LMP1 30-bp deletion. Hence, a total of seven
LMP1 strains, including the prototype B95–8 strain, were defined.
Earlier studies of EBV variants contained in blood and throat washings of healthy long term
viral carriers used spontaneous lymphoblastoid cell lines (LCL) transformed by viruses rescued
from these clinical samples and concluded that each individual only harbors one dominant
strain of virus [12]. Dual infections were later detected in clinical specimens of healthy individ-
uals [13] and of NPC patients [14], using restriction fragment length polymorphism (RFLP)
analysis of BamHI F fragment of EBV DNA. Multiple EBV variants were subsequently detected
in immunocompromised individuals, such as in human immunodeficiency virus (HIV)-
positive subjects [15,16] and in immunocompetent healthy donors [17–19], using PCR amplifi-
cation of different polymorphic genes of EBV genomes contained in clinical specimens. In
other studies, multiple EBNA1 subtypes could also be detected in peripheral blood mononucle-
ar cells (PBMC) and throat washings of healthy donors [20,21] and in those of NPC patients
[22].
Heteroduplex tracking assay (HTA) is a sensitive technique which can differentiate se-
quences with small number of differences and is capable of revealing multiple co-existing
strains in viral infections. It has been used to analyze the evolution of human immunodeficien-
cy virus (HIV) strains in patients who develop resistance to viral therapy [23]. In EBV
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genotyping studies, HTA served to distinguish the five EBNA2 groups and the seven LMP1
strains [24,25]. With use of HTA, co-infection of multiple EBV strains was found in asymp-
tomatic carriers and infectious mononucleosis [18,24,26]. Nonradioactive HTA has been devel-
oped for detection of variants in Plasmodium falciparum, using digoxigenin (DIG) label as the
detection system. [27]. In our study of EBV strains, 6-FAM fluorescent-label and direct fluores-
cent detection by ABI PRISM 377 automated sequencer were used to further reduce the steps
for signal detection.
The current understanding of EBV biology states that the virus infects both B cells and epi-
thelial cells. Whether multiple EBV strains can persist in or freely interchange between PBMC
(circulating B cell compartment), plasma and saliva (epithelial cell compartment) over time is
still unclear. In this longitudinal study, EBV strains harbored in cryopreserved serial samples
of PBMC, saliva and plasma from a cohort of children with serologically confirmed primary
EBV infection were analyzed, using typing assays (EBV1 and 2 and LMP1 deletion) and HTA
(EBNA2 and LMP1). The following questions were asked: Are multiple EBV strains acquired
at the start of primary infection? Do these strains persist in individual tissue compartments
and do they change within these compartments over time? Are the strains similar or different
between the tissue compartments? Any interchange of viral strains between the tissue compart-
ments? These are questions that are pertinent to further understanding of the natural distribu-
tion and interchange of multiple EBV strains within individual viral carriers.
Methods and Materials
Ethic statement
Clinical specimens were collected at Department of Paediatrics and Adolescent Medicine, The
University of Hong Kong, Queen Mary Hospital, between 2003 and 2006, after obtaining in-
formed written consent from the parents. The study is approved by Institutional Review Board
of The University of Hong Kong/Hospital Authority Hong Kong West Cluster for the purpose
of infectious mononucleosis studies.
Patients
Two study cohorts consisting of twelve children with infectious mononucleosis (IM) and eight
with asymptomatic primary infection (AS) were included. Children of age 18 or below with
symptoms and signs such as fever, cervical lymphadenopathy, tonsillopharyngitis and fatigue,
were recruited into the study as IM subjects. The AS subjects were identified serendipitously by
serological screening of children admitted to the general pediatric wards of Queen Mary Hospi-
tal, Hong Kong. The serological profile of primary EBV infection is defined as VCA IgM posi-
tive or negative, VCA IgG positive (low avidity) and EBNA negative. Peripheral blood samples
and saliva were collected at the time of clinical diagnosis (IM) or serological screening (AS)
and at 1 week, 1 month, 3 months, 6 months and 12 months after the diagnosis (for IM) or
screening (for AS).
Clinical samples and processing
Five to ten milliliter of blood was collected from each patient at each time point. After centrifu-
gation, PBMC were isolated by standard Ficoll-Hypaque density gradient method. Cells were
resuspended in 10% DMSO, 90% fetal bovine serum for storage. Plasma portion was further
centrifuged at 13000 rpm for 10 minutes followed by collection of supernatant to ensure that
cell-free plasma was obtained. The patient was also asked to chew for 1 minute on a cotton
wool cylinder of a salivette (Sarstedt, Nümbrecht, Germany), from which saliva was extracted
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by centrifugation at 2000 rpm for 10 minutes. PBMC, plasma and saliva samples were all cryo-
preserved until use.
Reference cell lines
Cell lines used as controls in our assays include B95–8 [28], Akata [29], Namalwa [30] and
Jijoye [31]. DNA was extracted from these cell lines. B95–8 contains type 1 EBV genome and
does not have the 30 bp deletion at the LMP1 locus, hence, was used as LMP1 wild-type non-
deleted control for LMP1 typing assay. Akata has the 30-bp deletion in LMP1 gene and was
used as LMP1 deletion control. Namalwa contains 2 copies of type 1 EBV genomes per cell and
was used as type 1 control for EBNA2 real-time PCR typing assay. Jijoye harbors a type 2 EBV
genome and was used as type 2 control for EBNA2 real-time PCR typing assay. All the above
cell lines were cultured, under aseptic condition, in RPMI-1640 (Gibco, Invitrogen, NY, USA)
supplemented with 10% FBS (Gibco BRL, USA) at 37°C in 5% CO2.
DNA isolation
DNA from PBMC was extracted by Qiagen DNeasy Blood & Tissue kit (QIAGEN, Hilden,
Germany). DNA from plasma and saliva was extracted by QIAamp DNA Blood Mini Kit
(QIAGEN).
Quantitative PCR for EBV loads in PBMCs, plasma and saliva
Quantitative PCR assays for EBV DNA in PBMCs were performed on ABI PRISM 7900 se-
quence detector (Applied Biosystems, Life Technologies, USA). EBV loads in PBMCs were de-
termined by amplifying EBV DNA polymerase (Pol, BALF5) gene and the input cell quantity
was determined by amplifying the human beta-2 microglobulin gene, as described previously
[32]. Namalwa cells were used as the standard. EBV loads in plasma and saliva were deter-
mined by amplifying the EBV BamH1W repeats of the EBV genome to achieve higher sensitiv-
ity [33].
Overall scheme of genotyping assays
This study utilized two typing assays, EBNA2 typing assay to discern type 1 and type 2 EBV
and LMP1 typing assay to discern LMP1 with or without the 30-bp deletion at the 3’ region.
We also employed two heteroduplex tracking assays (HTA) to distinguish the different type 1
EBNA2 and LMP1 variants. The EBNA2 variants were classified as group 1, 2, 3a, 3b and 3e.
[6] and the LMP1 variants as China 1 (C1) and Mediterranean + (M+) (both have the 30-bp
deletion) and China 2 (C2), Mediterranean—(M-), Alaskan (AL), North Carolina (NC) and
B95–8 (all without 30-bp deletion) [11]. The details of each typing assay and HTA are
described below.
EBNA2 real-time PCR typing
Real-time PCR typing assay was performed by ABI PRISM 7700 Sequence Detector (Applied-
Biosystem, USA). A common primer E2C (EBV coordinates 36522–36541, AGGGATGCCTG-
GACACAAGA) was used as forward primers for both EBV types. The type-specific reverse
primers for type 1 and 2 EBV were E2QR1 (36607–36628, TTAGCCATCCAAAG-
CATTCGCA) and E2QR2 (36549–36526, TTCTAAGAAGGTATTGAGCCATGC), respec-
tively. The 6-FAM-labeled E2_T1 (36751–36770, 6-FAM-TTGTGACAGAGGTGACAAAA)
and the VIC-labeled E2_T2 (36728–36709, VIC-TTGAAGAGTATGTCCTAAGG) were used
as probes to type 1 and 2 EBV genome, respectively. The reaction mixture were as follows:
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12.5 μl TaqMan Universal PCR Master Mix (Applied Biosystems, Branchburg, New Jersey,
USA), 0.25 μl E2C primer (10 μM), 0.25 μl E2QR1 primer (10 μM), 0.25 μl E2QR2 primer
(10 μM), 0.25 μl E2T1 probe (10 μM), 0.25 μl E2T2 probe (10 μM), 6.5 μl of distilled water and
5 μl of DNA with concentration of 50 ng/μl.
LMP1 30-bp deletion typing
PCR was performed to amplify the loci of 30bp deletion in the 3’region of LMP1. The forward
and reverse primers were designated LMPdelF (EBV coordinates 168369–168389, AGC-
GACTCTGCTGGAAATGAT) and FUE_FAM (EBV coordinates 168163–168183,
6-FAM-GTCATAGTAGCTTAGCTGAAC), respectively. GeneScan function of ABI PRISM
377 Automatic Sequencer (AppliedBiosystem, Foster City, CA, USA) was used to separate
FAM-labeled PCR products according to their size differences. 30-bp LMP1 variants migrate
faster than the undeleted wild type variants, resulting in separation of the two variants. Gel
mixture (7%) for 36cm plate was prepared as follows: 6ml of 5X TBE buffer, 4.2 ml of 10X
Long Ranger solution, 19.8ml of MilliQ water, 15 μl of TEMED and 150 μl of 10% ammonium
persulphate (APS). 2.5 μl mixtures of loading buffer and sample DNA annealed with FAM-la-
beled probe were loaded. The GeneScan was run with 1x TBE as the running buffer using the
ABI PRISM 377 Sequencer (Applied Biosystem, USA) at 48°C.
Heteroduplex tracking assays (HTA)
Probe for EBNA2 HTA was synthesized by PCR using the group 2 control plasmid (provided
by Dr R.J.Tierney, Cancer Research Institute for Cancer Studies, University of Birmingham).
The forward and reverse primers are E2SEQ7.1a (EBV coordinates 36671–36690, GCCA-
CAAGGCCCACAAACAG) and E2SEQ8.1_FAM (36901–36920, 6-FAM-AGGCCTTTG-
TAGTACCGTGA) respectively. Probes for LMP1 HTA were synthesized by PCR using the
control plasmids cloned with segments of LMP1 of the C2 and M+ strains (provided by Prof.
Nancy Raab-Raub, The University of North Carolina at Chapel Hill, USA). The primers used
are LMPdelF (167912–167932, AGCGACTCTGCTGGAAATGAT) and FUE_FAM (167705–
167725, 6-FAM-GTCATAGTAGCTTAGCTGAAC). The 6-FAM labeled probe was then gel
purified by QIAEX II Gel Extraction Kit (QIAGEN). Condition for the PCR reaction is as fol-
lows: 50°C for 2 minutes, 95°C for 10 minutes, repeat 45 times of 95°C for 15 seconds and 60
for 1 minute.
Nested PCR on sample DNA was performed. Primers for the first round of PCR for EBNA2
HTA were E2C and E2SEQ4.1 (37086–37067, GTAATGGCATAGGTGGAATG), and the sec-
ond round primers were E2SEQ7.1a and E2SEQ8.1a (36901–36920, AGGCCTTTGTAG-
TACCGTGA).
First round PCR primers for LMP1 HTA are LMP3UT-Eco (167559–167579, atcacgaggaatt-
cAATGTGGCTTTTCAGCCTAGA) and FUE_Eco (167705–167725, atcacgaggaattcGTCA-
TAGTAGCTTAGCTGAAC). The second round primers were LMPdelF and FUE_Eco. The
condition was the same for first and second round PCR and used the same condition as probe
synthesis. PCR products were gel-purified by QIAEX II Gel Extraction Kit (QIAGEN).
E2SEQ7.1a and E2SEQ8, and LMPdelF and FUE_Eco were used to amplify the reference
DNA segment from EBNA2 and LMP1 control plasmids, respectively, by the same PCR condi-
tion as above. The annealing reaction mixture was prepared as follows: 1 μl of 6-FAM-labeled
probe, 1 μl of annealing buffer (1M NaCl [Amresco, USA], 0.1M Tris [Amresco, USA] pH7.5,
20mM EDTA [Sigma, USA]), 8 μl of nested PCR product. The reaction mixture was heated at
100°C for 5 minutes and then put immediately in ice for 4 minutes. The same conditions were
employed to produce heteroduplexes for controls, where gel purified PCR products amplified
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from control plasmids were used instead of nested PCR product. Both C2 and M+ probes were
employed in LMP1 HTA to verify the identity of the LMP1 strains. ABI PRISM 377 Automatic
Sequencer was employed in both EBNA2 and LMP1 HTAs. Samples were run in 7% polyacryl-
amide gel together with the GeneScan Rox 400 ladder (Life Technologies, Grand Island, NY,
USA). 36°C was set for pre-run and GeneScan for LMP1 HTA while 48°C was set for EBNA2
HTA.
Sequencing analysis
Sequencing analysis was performed on about 10% of the PCR products of LMP1 HTA to vali-
date the HTA result. PCR products from these samples were sequenced in both forward and re-
versed direction with primers LMPdelF and FUE respectively. These PCR products were gel
purified by QIAEX II gel extraction kit (QIAGEN) to remove non-specific products and primer
dimers. BigDye Terminator v3.1 Cycle sequencing kit (Applied Biosystems, USA) was used
and the reaction mix was as follows: 1 μl BigDye Ready reaction mix, 1.5 μl BigDye sequencing
buffer, 1μl of 1.6 μM sequencing primer, 6.5 μl of water and PCR product. The reaction was
performed by GeneAmp PCR system 9700 (Applied Biosystems, USA) with the following reac-
tion conditions: 96°C for 1 minute, then repeating cycle of 96°C 10 seconds, 52°C 5 seconds
and 60°C 4 minutes for 25 times. The samples were sequenced in Genome Research Centre of
the University of Hong Kong on 3100 Genetic Analyzer (Applied Biosystems Division; Perkin-
Elmer Cetus).
Results
Typing and heteroduplex tracking assays of EBNA2 and LMP1 genes
An LMP1 typing assay was devised to differentiate the 30-bp deleted and non-deleted wild-
type. FAM-labeled PCR products were separated by electrophoresis and visualized on ABI
PRISM 377 Automatic Sequencer. Real-time PCR-based typing assay was performed to differ-
entiate type 1 and 2 EBV, as defined by EBNA2 gene polymorphisms, using type-specific prim-
ers. LMP1-specific HTA [25] and EBNA2 HTA [24] established in previous studies were
modified by using a 6-FAM fluorescent label instead of isotopic marker for probe labeling. In
LMP1 HTA analysis, samples were analyzed by the use of both C2 and M+ probes for cross-
checking. Fig. 1 illustrates the results of LMP1 typing assay and EBNA2 and LMP1 HTA, per-
formed on reference cell lines and plasmids, respectively. Quantitative PCR had been per-
formed on most of the cases and the viral loads expressed in per ml saliva or plasma, or per
million PBMCs are shown in S1 Table. Despite the use of nested PCR to increase sensitivity,
viral loads of approximately 500 copies per ml DNA were found to be the detection limit of
HTA.
IM and AS cases as cohort of primary EBV infection
EBNA2 and LMP1 typing and HTA were performed on all 20 cases, including 12 IM patients
and 8 asymptomatic individuals (AS). There was no observable difference between the strain
profiles of symptomatic and asymptomatic individuals.
Real-time PCR-based typing assay showed that in 14 out of 20 cases (70%), only type 1 ge-
nome was detected (Fig. 2). In four cases (IM5, IM7, IM11 and AS3), type 1 was the predomi-
nant strain, yet type 2 was also found co-existing in one to two time-points. In one case, IM12,
only type 2 genome was found in all samples. LMP1 30-bp deletion typing assay detected both
deleted and non-deleted strains in 75% of all cases (15/20), either co-existed in the same sam-
ple, or in a separate manner in samples of different compartment or time points (Fig. 2).
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Simultaneous detection of both deleted and non-deleted strains tend to be observed in PBMC
and plasma instead of in saliva. The saliva compartment of only four cases were detected to
have both deleted and non-deleted present and only two out of these four were having both
strains co-existing in a single sample at certain time point.
Fig 1. Controls and references for EBNA2 HTA, LMP1 typing and LMP1 HTA. (A) The references of EBNA2 HTA. Each of the five peaks represents a
reference strain defined using EBNA2 polymorphisms as defined by Schuster et al [6]. A ROX ladder was loaded to the same lane to indicate the relative
positions of the peaks. Since group 2 reference is used as the probe, group 2 strains will be visualized as the peak with highest mobility (left most), followed
by group 1 peak. Group 3e, 3b and 3a have lower sequence similarities to those of group 2, and hence, formed heteroduplexes of lowest mobility (right most).
(B) Controls for LMP1 typing assay. PCR products from Akata and B95.8 DNA represent the 30-bp deleted and non-deleted LMP1 strains, respectively.
Sample DNA will be PCR-amplified by 6-FAM labeled primers and loaded into lanes adjacent to the controls. Positions of the peaks will be directly compared
to those of the controls to determine the results of the LMP1 genotyping. (C) The references of LMP1 HTA. Each of the seven peaks represents a reference
strain defined using LMP1 polymorphisms as defined by Edwards et al [11]. This figure illustrated the clear separation of the seven reference LMP1 plasmids
by the HTA using 6-FAM-labeled PCR product of M+ reference plasmid as the probe.
doi:10.1371/journal.pone.0120710.g001
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Fig 2. EBNA2 and LMP1 Typing assays on 20 cases. EBV types as defined by EBNA2 (type 1 or 2) and LMP1 (30-bp deleted or wild-type) are illustrated
as colored boxes. Each box represents a sample in one of the three compartments, peripheral blood mononuclear cells (B), plasma (P) and saliva (S), at a
certain time-point, up to 1 year since diagnosis.
doi:10.1371/journal.pone.0120710.g002
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All of the five EBNA2 defined groups can be detected with EBNA2 HTA in our cases
(Fig. 3). Multiple EBNA2 strains were detected in all 20 cases, with 5 cases having 2 strains, 10
cases having 3 strains and 5 cases with 4 strains (Table 1). Group 1 had been found in 18 out 20
cases (90%), group 2 in 15 cases (75%), group 3b in 13 cases (65%), and group 3e in 12 cases
(60%). Group 3a could only be detected in one case (5%). Groups 2 and 3b were found more
frequently in plasma than PBMC and saliva samples of the cases (Table 2).
LMP1 HTA clearly demonstrated the presence of more than one viral strain in all subjects
(refer to Fig. 3). Co-infection of four strains was found in two cases (10%), three strains in 12
cases (60%) and two strains in 6 cases (30%) (Table 1). The most common strain found was
C1, which was present in 17 cases (85%). C2 in 16 cases (80%), M+ in 15 cases (75%), North
Carolina (NC) in six cases (30%), and M- in only one case. None of the cases harbored Alaskan
(AL) or B95.8 strain. C1 were found more frequently in PBMC and saliva than plasma samples,
while M+ were observed more frequently in plasma (refer to Table 3). The LMP1 HTA results
corresponded to those of LMP1 typing assay but showed a greater diversity. This likely reflects
a difference of sensitivity between the assays.
Multiple EBV strains acquired in early infection
The analyzed profiles of three assays, EBNA2 and LMP1 HTA, and LMP1 typing assay, per-
formed on case IM4, are illustrated in Fig. 4. Group 3e and group 2 were the major groups
found in this case by EBNA2 HTA. LMP1 variants C1, M+ and C2 were commonly detected at
multiple time-points in PBMC and saliva.
Multiple strains can be captured by looking across different compartment through the com-
bination of different assays. EBNA2 defined group 3e and group 2 are found at day 0, in PBMC
and saliva, and in plasma, respectively. At the sample time-point, 30-bp deleted (del) strain was
observed in all three compartments, while M+, C1, and C2 were detected by LMP1 HTA. The
two HTAs have already shown the presence of multiple strains in a case at the first time-point.
Two strains, M+ and C2, were seen in early time-points of plasma samples of IM4 by LMP1
HTA. Similarly, in PBMC, we observed the presence of group 3e and del strain, yet C1 and C2
is found by LMP1 HTA. IM4 was not the only case which multiple EBV strains have been
found in early time-points. Multiple strains were also found at day 0 of 17 cases, as illustrated
by at least one of the typing assays or HTAs. When both HTAs are considered jointly, the ana-
lyzed result may represent more strains than observed in either assay in isolation, due to in-
complete linkage of EBNA2 and LMP1 genes. This shows that EBNA2 and LMP1 HTAs are
complementary to one another in strain detection.
Stable persistence of virus in the three compartments
LMP1 and EBNA2 strains were recurrently detected in consecutive time-points in PBMC and
saliva, and sometimes in plasma, in majority of the cases. EBNA2 HTA analysis of IM4
(Fig. 4A) showed that group 3e persisted in PBMC and saliva in all five time-points, while
group 2 was observed in all longitudinal plasma samples. Similarly, C1 and C2 strains were
identified by LMP1 HTA in PBMC, M+ and C2 in plasma, and C1 in saliva, in many of the
time-points of IM4 (Fig. 4C).
Group 1, C1 and NC in PBMC, group 1 and C1 in saliva, and group 2 and M+ in plasma of
IM4, persisted stably through multiple time-points. Group 3e, M+ and C2 in PBMC of IM6,
group 2, M+ and C2 in plasma, and group 3e, C1, and C2 in saliva of the same case, again
showed persistence through multiple time-points (Fig. 3).
In IM10 (Fig. 5A), all PBMC samples harbored C1 and C2 simultaneously, while in saliva,
all samples were detected with China 1 only. Group 1 was found in all time-points of IM12 in
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Fig 3. EBNA2 and LMP1 HTA on 20 cases. EBV strains as defined by EBNA2 (group 1, 2, 3a, 3b and 3e) and LMP1 (B95–8, M+, M-, C1, C2, AL, NC) are
illustrated as colored boxes. Each box represents a sample in one of the three compartments, peripheral blood mononuclear cells (B), plasma (P) and saliva
(S), at a certain time-point, up to 1 year since diagnosis.
doi:10.1371/journal.pone.0120710.g003
EBV Strains among Tissue Compartments
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PBMC and plasma (Fig. 5B), and in three out of five time-points in saliva. M- was detected in
every time-points of PBMC and saliva of IM12, M+ in all plasma samples, and C2 in majority
of samples in the three compartments.
Despite the general persistence of the dominant strain, minor strains were observed in most
of the cases, either co-existing with or displacing the dominant strain at one or more time-
points. For example, EBNA2 HTA analysis of IM7 showed that group 2 was predominant in
plasma, yet at 1 month, group 1 was detected. LMP1 HTA analysis of IM1 found C1 and NC at
day 0 or both PBMC and plasma. These two strains persisted in PBMC, yet in plasma it was re-
placed with M+, and this M+ became the dominant strain later. Relative abundance of a strain
might vary across time, hence, it might become detectable at certain time-point and
disappeared thereafter.
Interchange of virus among different compartments
Interchange and transmission of virus among compartments was demonstrated by HTA in
multiple cases. For example, group 3b appears first in plasma at 1 month of IM5 (Fig. 2), then
in saliva at 6 months. This suggested a transmission of the virus from plasma to saliva. Since
group 3e was detectable in PBMC and saliva samples collected at day 0, the group 3e strain ob-
served at day 14 plasma sample might come from PBMC and saliva. LMP1 HTA showed that
M+ was first detected in saliva at day 14, and appearing later at 6 months in PBMC. This sug-
gested the M+ entered PBMC from saliva. In IM7 (Fig. 3), group 1 in plasma at 1 month might
come either from PBMC or saliva, since group 1 is the dominant EBNA2 defined strain in
these two compartments. By LMP1 HTA we also detected C2 at 12 months in saliva, not in pre-
vious time-points of saliva. PBMC and plasma can be the source of this C2. Occasional pres-
ence of group 1 in plasma of AS1, AS3 and AS7 might also due to transmission from PBMC
and saliva. Assuming a virus is not eliminated from the body once infected a cell, emergence of
a strain mid-way in our longitudinal study might indicate either a rise in relative abundance of
a dormant strain, or transmission of this previously absent strain from other compartments.
Table 1. Number of cases in which a certain number of strains were detected.
EBNA2 typing EBNA2 HTA LMP1 typing LMP1 HTA
no. of cases no. of cases no. of cases no. of cases
type 1 only 14 1 strain 0 wt only 0 1 strain 0
type 2 only 1 2 strains 5 del only 5 2 strains 6
type 1 & 2 5 3 strains 10 wt & del 15 3 strains 12
4 strains 5 4 strains 2
doi:10.1371/journal.pone.0120710.t001
Table 2. Distribution of strains by EBNA2 HTA.
PBMC Plasma Saliva
group 1 13 13 13
group 2 3 13 5
group 3a 0 1 2
group 3b 3 12 2
group 3e 10 12 9
*Number of samples containing the strain.
doi:10.1371/journal.pone.0120710.t002
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Concordance of viral strains in PBMC and saliva compartments
EBNA2 HTA performed on IM1, IM3, IM4, IM6, IM7, AS2, AS5 and AS7 displayed a close re-
semblance of strains detected between PBMC and saliva samples. Group 1 predominates in
both PBMC and saliva of IM1, IM2, IM3, IM7, AS1 and AS7, while group 3e was observed in
multiple time-points of PBMC and saliva samples of IM4, 5, 6, AS2 and AS5. Nevertheless,
group 1 and 3e can also be detected in some of the cases in plasma, indicating that infection by
these strains was not exclusive to the compartments of PBMC and saliva. The remaining sub-
types, namely, group 2, 3a, and 3b, were detected as minor strains in PBMC and saliva. None of
these five groups are exclusively found in any of the compartments.
EBNA2 HTA of IM4 (Fig. 4) illustrated that group 3e strain was present in almost all
PBMC and saliva samples. Group 1 strain was detected only in the 12 month PBMC sample,
but neither present in earlier time points nor in simultaneously collected saliva and plasma
samples. Group 2 strain was only present in plasma samples of all time-points, not in PBMC
or saliva.
IM1 and IM6 (Fig. 3) also show the difference between plasma and the other two compart-
ments. Clear discordance of plasma from PBMC and saliva in IM1 is shown by EBNA2 HTA
analysis. Group 1 is the only strain detected in PBMC and saliva, while only group 2 is observed
in plasma. Similarly, LMP1 HTA of IM1 shows that C1 is mainly found in PBMC and saliva,
while M+ is only found in plasma. Such discordance can also be observed in IM6 (Fig. 3).
Group 3e is the dominant strain in PBMC and saliva, while group 2 is dominant in plasma.
Greater diversity of viral strains in plasma
EBNA2 HTA of IM10 and IM12 revealed a great diversity of strains in the plasma compart-
ment (Fig. 5). Group 3e was the only group found in PBMC and saliva of IM10 by EBNA2
HTA. In the contrary, four groups, group 1, 2, 3b and 3e, were detected in plasma (Fig. 5A). In
plasma of IM12 (Fig. 5B), two groups, group 1 and 3b, were observed simultaneously in all
time-point, except at 1 month, where there were three groups, group 1, 3b and 3e, co-existing.
Only one to two strains were observed in PBMC and saliva of IM12. LMP1 HTA also showed
three strains, M+, M- and C2, co-existing in first two time-points of plasma in IM12.
Four LMP1 strains, C1, C2, M+ and NC, were detected in plasma of IM8 (Fig. 2). Only C1
was detected in most of the time-points in PBMC and saliva of the same case. Three EBNA2
strains, group 1, 2 and 3b, were observed in plasma of AS7, yet only group 1 was seen in PBMC
and saliva. Other examples which have three or more strains observed in plasma by either
EBNA2 or LMP1 HTA analysis include IM2, IM7, IM9, IM11, IM12, AS1 and AS4 (Fig. 2).
Table 3. Distribution of strains by LMP1 HTA.
PBMC Plasma Saliva
C1 17 11 15
C2 13 16 15
M+ 9 14 4
M- 1 1 1
NC 4 4 3
B95–8 0 0 0
AL 0 0 0
*Number of samples containing the strain.
doi:10.1371/journal.pone.0120710.t003
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Validation of HTA results by Sanger sequencing
In order to validate the strains detected in EBNA2 and LMP1 HTA, sequencing analysis was
performed on a subset of the EBNA2 and LMP1 nested PCR products. Cycle sequencing was
performed in about 10% of the samples in both directions for verification. Sequences obtained
from the selected samples were all concordant to the results of HTA.
LMP1 HTA performed on day 0 PBMC sample of IM12 showed that the heteroduplexes
were identified at a position differ from the references. Sequencing analysis revealed four nucle-
otides different from the M- reference sequence. These non-synonymous nucleotide changes
lead to amino acid changes of the translated protein at residues 335 (Gly to Ala), 352 (His to
Arg) and 366 (Ala to Thr). Amino acid changes at residue 352 and 366 were reported in previ-
ous study as non-strain-determining changes in Mediterranean variant [34]. These mutations,
therefore, represent the sequence variability of a strain within a population.
Fig 4. LMP1 typing, EBNA2 HTA, LMP1 typing and HTA of IM4. (A) EBNA2 HTA (B) LMP1 typing in panel D, E and F (C) LMP1 HTA in panel G, H and I.
Red peaks represent the ROX ladder. The first rows of EBNA2 HTA and LMP1 typing profiles show the controls. The strains detected were labeled beside
the corresponding blue peaks. D0, D14, 1m, 3m, 6m and 12m represents time points of day 0, day 14, 1 month, 3 months, 6 months and 12 months,
respectively. A summary of strains detected in this case is in Fig. 2 and 3.
doi:10.1371/journal.pone.0120710.g004
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Fig 5. EBNA2 HTA and LMP1 HTA of IM10 and IM12. (A) EBNA2 HTA and LMP1 HTA of IM10 (B) EBNA2 HTA and LMP1 HTA of IM12. Red peaks
represent the ROX ladder. The left, middle and right panel represents samples from PBMC, plasma and saliva, respectively. The strains detected were
labeled beside the corresponding blue peaks. D0, D14, 1m, 3m, 6m and 12m represents time points of day 0, day 14, 1 month, 3 months, 6 months and 12
months, respectively. A summary of strains detected in this case is in Fig. 2 and 3.
doi:10.1371/journal.pone.0120710.g005
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Discussion
Typing assays and HTA were performed on 20 cases, which included 12 childhoodinfectious
mononucleosis (IM) and 8 asymptomatic (AS) cases of primary EBV infection. Since there
was no observable difference between the strain profiles of IM and AS subjects, these 20 cases
can be considered as one cohort of EBV primary infection for the purpose of this study. The
relative prevalence of types 1 and 2 EBV was in line with previous studies, which stated
the type 1 EBV is prevalent in east and south Asia [3]. EBNA2 typing and LMP1 30bp
deletion typing demonstrated that more than one strain can be present in a single sample.
With the strength of identifying more than two genotypes at loci of interest, HTA provided ad-
ditional useful information in this viral strain study. More importantly, since linkage between
EBNA2 and LMP1 genes was not observed, the combination of EBNA2 and LMP1 HTA
would provide greater discriminatory power on the detection of EBV strains than any single
assay alone.
Presence of multiple strains was found in blood and saliva specimens collected simulta-
neously at the first time-point in the majority of the cases studied. These samples can be con-
sidered as a snapshot of strain profile at early stage of infection of that individual. Based on our
current understanding of EBV biology, the virus transmitted mainly via saliva exchange. Saliva
specimen, at any single time-point, was observed to rarely hold more than two viral strains. In
the light of previous studies, showing preexisting host immunity to EBV might not necessarily
protect against future EBV infections [35], it is possible that multiple strains were acquired
from multiple carriers, with each carried one or two EBV strains, at the early stage of infection.
In addition to EBV, multiple infections of human cytomegalovirus in healthy individuals [36]
and Kaposi's sarcoma-associated herpesvirus in HIV-positive and negative individuals [37]
were also reported, suggesting that multiple infection is a feature common in herpesvirus.
Consistent strains were observed in multiple time-points in our longitudinal study. The cur-
rent model of EBV life cycle states that the growth program of the virus activates infected B
cells to become proliferating blasts, they then differentiate into resting memory B cells through
the process of the germinal-center reaction [38]. Some of these latently infected B cells will go
into the peripheral circulation. The virus detected in PBMC, hence, represents a B-cell pool in
circulation. On the other hand, the virus detected in saliva represents the epithelial pool, re-
leased from lytic replication of epithelial cells. The same virus strains were consistently detected
in longitudinal samples of the same compartment implied that the two pools of virus persist
stably throughout the one year of sample collection in our study. Despite the general consisten-
cy of detected strains through time, temporal changes in EBV strains were observed in sequen-
tially collected specimens in the same individual. Due to the limitation of assay sensitivity, we
could notprove conclusively the occurrence of sequential infection events. Emergence, disap-
pearance and re-emergence of viral strains in our assays might reflect a change in relative abun-
dance of co-infecting viral strains or an interchange of viruses among different compartments
Resemblance of strain profiles in PBMC and saliva reflected the intimate interaction be-
tween viruses released from the epithelial cells and circulating B cells, as part of the EBV life
cycle. It is known that oral cavity and peripheral circulation are important anatomical sites of
EBV infection and persistence. These two compartments are connected by orophayngeal lym-
phoid tissues such as the lingual, palatine, and pharyngeal tonsils. EBV-infected B-cells might
re-enter the tonsils though the mechanism of lymphocyte homing, in which memory lympho-
cytes express characteristic sets of adhesion receptors in order to return to the target organs
where they first encountered antigens [39,40]. EBV-infected cells can therefore release the viral
particles through lytic replication, re-infect the cells in the lymphoepithelial tissues, and subse-
quently release viruses into the oral compartment[41,42]. Such an intimate and dynamic
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relationship allows EBV strains to equilibrate in these two compartments, hence, gives rise to
close resemblance in the strain profiles.
Although infectious virions are also present in long-term virus carriers [43], attempts in typ-
ing EBV genome in plasma samples in healthy carriers were sometimes rendered futile due to
low viral loads. Heightened viraemia in primary infection, though, provide us a chance to
study the strains present in the plasma. Discordance of strains in plasma to those in PBMC and
saliva was observed in a proportion of the cases. LMP1 HTA performed on Caucasian samples
of primary infection patients also showed distinctive strains in plasma [26]. Since viruses har-
bored in multiple anatomical sites might be shed into the plasma, our findings might suggest
that distinct viral strains can be harbored in hitherto undetermined tissue compartments. In-
deed, EBV could be detected in different tissues at various anatomical locations of the human
body [19].
In summary, this study indicated that multiple viral strains were acquired early at the start
of infection. Dominant EBV strains were observed to persist stably in the same tissue compart-
ment over time. Interchange of viruses between circulating B cell and epithelial cell pools is
suggested by the concordance of EBV strains between PBMC and saliva, whilst discordant viral
strains observed in plasma and PBMC/saliva is suggestive of the presence of distinct viral
strains in hitherto undetermined compartments. Taken together, the results indicated that the
distribution, persistence and interchange of viral strains among the tissue compartments are
more complex than those proposed by the current model of EBV life cycle.
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